Content PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2

Size: px
Start display at page:

Download "Content PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2"

Transcription

1 EMA, FDA- ANDA Readiness -OSD Generics Solution Post Formulation Development Horch Guo, May. 2016, Changzhou, China

2 Content PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2

3 PART I: ANDA Roadmap 3

4 ANDA Product Development Roadmap - QbD based 1 Market Survey & Kick-off 2 Pre- Formulation 3 Formulation Development 4 Process Dev. & Scale-UP 5 Exhibit batches(pv) 6 ANDA Filing -Raw Materials -QTPP -Raw Materials Audit -Equip. Qualification -PV Protocol -Mfg. & Ana Equip. -Mfg Rooms -Containments -CQAs -CMAs -Method of Mfg.Dev. -CV Method Develop. -Tooling -CPPs & CQAs -Method of Mfg. (IPC,Sampling) Dev. -Method of Mfg. (IPC,Sampling) -Method of Pkg. -CV -Process Varialbes & Range -Method of Pkg. Dev. -Scale-UP -CV Protocol 4

5 QTPP & & CQA & CPPs 5

6 PART II: CPPs & CQAs 6

7 Quality Right at First Time -QbD - QbD Concept Product Knowledge Process Understanding Product Specification Product Quality Attributes Process Parameters Process Controls Product Performance Product Design Process Design Process Performance -Desired Clinical Performance -Dosage Form -Excipients -Stability -Unit Operations -Control Strategy -Cpk -Robustness 7

8 Quality Right at First Time - Patient based integrated RA (Q8, Q9, Q10) ICH Q8/9/10- Patient based risk assessment QMS: ISO 9001:2005 8

9 Quality Right at First Time - Design Space & Robustness Quality issue & Cost Design Parameter Design Space Operation Range Design Space Knowledge Space 9

10 Quality Right at First Time - Operation / Design Space & Robustness Critical Process Parameter (CPP) A process input that must be kept within a proven acceptable range (PAR) in order to ensure that the final product will be within its CQA limits Process Understanding Critical Quality Attribute (CQA) a process output which is critical to achieving the product quality/safety/efficacy (e.g. impurity profile, stability, dissolution) Robust Process Normal Operating Range (NOR) Non-Robust Process Normal Operating Range (NOR) Proven Acceptable Range (PAR) Proven Acceptable Range (PAR)

11 Quality Right at First Time -Operation Process/ Reliable & Robust Risk Assessments (FMEA) -The Variability on CPPs Critical Process Parameter (CPP) -Intrinsic API properties (solubility, stability) -Formulation Principle -Manufacturing Costs -Volume considerations Technology -Wet Granulation -Dry Granulation -Extrusion Process Design -Define the CPPs and PARs Process Control Strategy -Control Range

12 Quality Right at First Time -Operation/ Variations Control key points People Equipment/Utilities Environment Materials Profile & education Adequate design Zone concept Specifications Job description Measurement systems containment Supplier management Regular training Specifications Layout Packaging Supervision Qualification Hygiene Storage/transport Communication Calibration Microbiology monitoring Testing Procedures Maintenance Pest control Rewarding Cleaning Unknown variations are the major threat for Quality ( We do not know what we do not know )

13 OSD -Operation & PPs & QAs Operation Process Parameter Quality Attributes Milling Wet granulation -Mill type -Speed -Blade configuration/type -Screen type and size -Feed rate High Shear Granulation -Pre-binder mixing time -Impeller speed/configuration/location -Chopper speed/configuration -Spray nozzle type/location -Method of binder addition -Binder fluid temperature -Binder addition rate/time -Post-granulation mix/kneading time -Bowl/product temperature -Power consumption (kw) -Particle size distribution -Particle shape -Bulk/tapped density -Flow properties -Polymorphic form -Moisture content -Flow property -Particle size and distribution -Granule size and distribution -Bulk density Wet granulation 13 Fluid Bed Granulation -Mixing time -Spray nozzle type/number/pattern/configuration -Method of binder addition -Binder fluid temperature -Binder fluid addition rate/time -Inlet airflow, temperature, volume and dew point -Exhaust air temperature and flow rate -Filter property and size -Filter shaking intervals -Product temperature -Moisture content -Flow property -Particle size and distribution -Granule size and distribution -Bulk density

14 OSD-Operation & PPs & QAs Operation Process Parameter Quality Attributes Drying Fluid Bed Dryer -Inlet air volume, temperature, and dew point -Exhaust air temperature and flow -Filter properties -Filter shaking intervals -Product temperature -Total drying time -Granule size and distribution -Granule strength and uniformity -Particle size -Flow -Bulk/tapped density -Moisture content -Residual solvents Drying Mixing Tray Dryer -Number of carts and trays per chamber -Amount of product per tray -Drying time and temperature -Airflow -Inlet air dew point -Vacuum/microwave dryer -Jacket temperature -Condenser temperature -Impeller speed -Vacuum strength -Microwave frequency -Electric field -Energy supplied -Product temperature -Type and geometry of mixer -Order of addition -Mixer load level -Time of rotations -Holding time for final blend -Granule size and distribution -Granule strength and uniformity -Particle size -Flow -Bulk/tapped density -Moisture content -Residual solvents -Blend uniformity -Particle size distribution -Bulk/tapped density -Moisture content -Flow properties 14

15 OSD -Operation & PPs & QAs Operation Process Parameter Quality Attributes Dry Granulation -Roller type -Roll speed -Gap setting -Roll pressure force -Temperature -Roller gap -Auger screw rate -Appearance -Ribbon/particle size and shape -Ribbon density, strength, and thickness -Moisture content Compression Coating -Compression speed and force -Precompression force -Feed frame type and speed -Hopper design, height, and vibration -Tablet weight and thickness -Depth of fill -Punch penetration depth -Total pre-heating time -Spray nozzle type/number/pattern/configuration -Individual gun spray rate -Total spray rate -Pan rotation speed -Atomization air pressure -Pattern air pressure -Inlet airflow, temperature, and dew point -Exhaust air temperature and airflow -Product temperature -Total coating time -Target tablet weight -Weight uniformity -Content uniformity -Hardness -Thickness -Tablet porosity -Friability -Visual attributes - -Weight of core tablets -Appearance -Visual attributes -% Weight gain -Film thickness -Color uniformity -Hardness -Thickness -Friability 15

16 PART III: Scale-Up and Technology Transfer 16

17 Scale-Up & Technology Transfer 17

18 Scale-Up Wet Granulation CQAs related -Flow property -Particle size and distribution -Granule size and distribution -Bulk density -API & Excipients ratio -Binding solution properties CPPs related 18

19 Scale-Up Dry Granulation CQAs related -Particle size & Particle size distribution -Particle flowability -Particle shape -API & excipients ratio CPPs related Scale Batch Size(Kg) Roller width (mm) Roller diameter (mm) Roller gap (mm) Roller pressure (bar) Mill Screen orifice size (mm) Lab Pilot Commercial

20 Scale-Up Blending & Lubrication Scale Batch Size(Kg) Blender Capacity (L) CQAs related -Particle size & Particle size distribution -Particle flowability -Particle shape -API & excipients ratio Volume Fill Level (%) Rotation Speed (rpm) Final Blending (min) Lubrication (min) Lab Pilot Commercial CPPs related 20

21 Scale-Up Coating 21

22 PART IV: Process Validation & Sampling 22

23 PV Lifecycle 制 业 药 23

24 CPP & CQA & PV -Quality Risk Management 24

25 PV-Quality Risk Management A successful validation program depends on information and knowledge from product and process development 25

26 PV -Deliverables 26

27 PV Sampling plan e.g. Blending Step Sampling Test Sample a minimum of 10 locations distributed throughout the mixer/blender at three different levels (top, middle and bottom). Assay (potency) In-process controls Holding time Sample size should not be greater than three times (3X) the weight of the dosage unit. Sample quantities larger than 3X can be used if they can be scientifically justified. Composite sample 27

28 Cleaning -Validation phase- Cleaning Validation Evaluation on the critical points for the equipment selection and design 3 continuous CV for campaign production CV Sampling Identify Product & Process contacted surface area and risk evaluation Develop the equipment based cleaning recipe and CVP QC analysis Cleaning Validation Master Plan Develop and validate the analysis method (API residual and recovery testing) Cleaning Validation Report 28 -Cleaning Validation team with early involvement is most important for cleaning & cross-contamination!

29 More information... Authorities:

30 30

31 Thanks for your attention! 31

Quality by Design (QbD)

Quality by Design (QbD) Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,

More information

A Framework and Case Study for Implementing the New Process Validation Guidance

A Framework and Case Study for Implementing the New Process Validation Guidance A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing

More information

Stage 3 - Process Validation: Measuring what matters

Stage 3 - Process Validation: Measuring what matters Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company

More information

How to Identify Critical Quality Attributes and Critical Process Parameters

How to Identify Critical Quality Attributes and Critical Process Parameters How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,

More information

Applied Process Understanding in Drug Product Development

Applied Process Understanding in Drug Product Development Applied Process Understanding in Drug Product Development A combined pharmaceutical science, materials science and chemical process engineering approach 17 October, Heidelberg, Germany ir Sander van den

More information

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015 Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development S Betterman 15Apr2015 Agenda Background Implementation Strategy Infrastructure Building Project Application

More information

Quality by Design, Revolution or Evolution? Wim Oostra

Quality by Design, Revolution or Evolution? Wim Oostra Quality by Design, Revolution or Evolution? Wim Oostra 1993 1998 2007 2009 2013 And many more.. Content Introduction A bit of history Examples A New product Legacy product Today? The triggers The goal

More information

PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany

PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany ir Sander van den Ban, CEng The Unpredictability of

More information

QbD implementation in Generic Industry: Overview and Case-Study

QbD implementation in Generic Industry: Overview and Case-Study QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They

More information

Control Strategy. Implementation of ICH Q8, Q9, Q10

Control Strategy. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session

More information

Roller Compaction: New trends, challenges and solutions

Roller Compaction: New trends, challenges and solutions Roller Compaction: New trends, challenges and solutions TODD STUTZMAN, PHARM.D. R.PH. DIRECTOR, PHARMACEUTICS SARAH PYSZCZYNSKI, PH.D. PRINCIPAL SCIENTIST 21FEB2017 2017 Catalent Pharma Solutions. All

More information

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur

Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended

More information

ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment

ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation

More information

Better wet granulation: development, scale-up and manufacture

Better wet granulation: development, scale-up and manufacture Better wet granulation: development, scale-up and manufacture By Tim Freeman, Freeman Technology Wet granulation is a common unit operation in the pharmaceutical industry yet accurate endpoint detection

More information

SUPAC IR/MR Update. Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013

SUPAC IR/MR Update. Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013 SUPAC IR/MR Update Glenn Van Buskirk, Ph.D. PQRI Lead Author April 2013 Why do it? SUPAC IR/MR Update Oral solid dosage forms continue to be the most significant class of drug product submissions to FDA

More information

Continuous Manufacturing

Continuous Manufacturing Continuous Manufacturing Continuous ing in the Industry Continuous processing has been adopted by the majority of process industries for the manufacturing of fluids (i.e. liquids and gasses) and solids

More information

A Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals

A Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals Review Article Hardik Patel* 1, Shraddha Parmar 1, Bhavna Patel 1 1 Post Graduate Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India. *Corresponding author

More information

Sakura Bloom Tablets P2 Mock

Sakura Bloom Tablets P2 Mock Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a

More information

Basic Aspects of Process Validation of Solid Oral Dosage Forms

Basic Aspects of Process Validation of Solid Oral Dosage Forms Review Article Basic Aspects of Process Validation of Solid Oral Dosage Forms Sharma Tejal Department of Pharmaceutics, B. N. Girls College of Pharmacy, Udaipur (Raj.) 313002(India) Validation of the manufacturing

More information

Quality by design: A holistic concept of building quality in pharmaceuticals

Quality by design: A holistic concept of building quality in pharmaceuticals Available online at www.pharmscidirect.com Int J Pharm Biomed Res 2012, 3(2), 100-108 Review article International Journal of PHARMACEUTICAL AND BIOMEDICAL RESEARCH ISSN No: 0976-0350 Quality by design:

More information

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015 Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route

More information

Continuous Processing. MODCOS for Continuous Oral Solid Dosage Production Textmasterformat in Mastervorlage eingeben

Continuous Processing. MODCOS for Continuous Oral Solid Dosage Production Textmasterformat in Mastervorlage eingeben Continuous Processing MODCOS for Continuous Oral Solid Dosage Production 1 Why continuous production 2 Why Continuous Production? Saving manufacturing costs High productivity because of substantial time

More information

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14

More information

Validation of Pharmaceutical Manufacturing Process Focus: APIs.

Validation of Pharmaceutical Manufacturing Process Focus: APIs. Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised

More information

Meeting Solid Dose Formulation Challenges

Meeting Solid Dose Formulation Challenges Streamlining (Fast Tracking) Solid Dosage Form Development Tony Carpanzano, B.S., R. Ph. Director, Research & Development Streamlining (Fast Tracking) Solid Dosage Form Development Meeting Solid Dose Formulation

More information

Maximizing Roller Compaction Benefits with Proper Excipient Selection

Maximizing Roller Compaction Benefits with Proper Excipient Selection A sponsored whitepaper. Maximizing Roller Compaction Benefits with Proper Excipient Selection By: Bernhard Fussnegger, Global Development and Technical Marketing, PVP/Coatings, Instant & Modified Release,

More information

Regulatory Assessment

Regulatory Assessment Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal

More information

Developing new drug products is very expensive, especially

Developing new drug products is very expensive, especially As appeared in March 2018 Tablets & Capsules www.tabletscapsules.com formulation Developing fixed-dose combinations Amar Patel, Bruhalkumar Shah, Deep Patel, Satish Shetty, and Anthony Qu Halo Pharmaceuticals

More information

University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester

University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting

More information

Inspection. Implementation of ICH Q8, Q9, Q10

Inspection. Implementation of ICH Q8, Q9, Q10 Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory

More information

Short review on Quality by design: A new Era of Pharmaceutical drug development

Short review on Quality by design: A new Era of Pharmaceutical drug development International Journal of Drug Development & Research July-September 2012 Vol. 4 Issue 3 ISSN 0975-9344 Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands SJR

More information

Tablet formulation design spaces for direct compression and roller compaction. QbD in Pharmaceutical Development: processes

Tablet formulation design spaces for direct compression and roller compaction. QbD in Pharmaceutical Development: processes QbD in Pharmaceutical Development: Tablet formulation design spaces for direct compression and roller compaction processes Morten Allesø, PhD (MSc Pharm) Pharmaceutical scientist ISPE Nordic PAT CoP, June

More information

Conducting Supplier Audits: Ensure Validation Compliance

Conducting Supplier Audits: Ensure Validation Compliance Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why

More information

Scientific and Regulatory challenges in Quality by Design (QbD) submissions

Scientific and Regulatory challenges in Quality by Design (QbD) submissions Health Santé Canada Canada Scientific and Regulatory challenges in Quality by Design (QbD) submissions Krishnan R. Tirunellai, Ph. D. Bureau of Pharmaceutical Sciences TPD, Health Canada CVG, October 2007

More information

Available through Online

Available through Online ISSN: 0975-766X CODEN: IJPTFI Available through Online Review Article www.ijptonline.com PROCESS VALIDATION OF CRITICAL STEPS INVOLVED IN MANUFACTURING OF SOLID DOSAGE FORMS IN PHARMACEUTICAL INDUSTRY

More information

Process Design Risk Management A Proactive Approach

Process Design Risk Management A Proactive Approach Page 1 of 7 Guest Column August 30, 2017 Process Design & Risk Management A Proactive Approach By Sandra Wassink, Principal Process Engineer, Pharmatech Associates The FDA has given us the green light

More information

Optimization of a Continuous Wet Granulation Process by Understanding Granule Properties

Optimization of a Continuous Wet Granulation Process by Understanding Granule Properties Optimization of a Continuous Wet Granulation Process by Understanding Granule Properties Presented By Andrew Birkmire Process Development Manager GEA Process Engineering Presentation Outline Description

More information

QbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS

QbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS QbD QUANTITATIVE MEASUREMENTS OF CQAS IN SOLID DOSAGE FORM UNIT OPERATIONS Porosity Density Surface Area USP USP USP Porosimetry by Mercury Intrusion Density of Solids - Gas Pycnometry

More information

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries

Int. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,

More information

Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics

Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics By Fernando Muzzio, Marianthi Ierapetritou, Rohit Ramachandran, Amanda

More information

WHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS

WHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS 23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT

More information

coating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies

coating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies As appeared in Tablets & Capsules April 201 coating www.tabletscapsules.com Layering an API onto tablets using a perforated-drum coater: A case study Vasant Shetty, Sameer Borate, Anuprita Landge, and

More information

NIRS, PAT, RTR testing EU experience and regulatory perspective

NIRS, PAT, RTR testing EU experience and regulatory perspective NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in

More information

2nd FDA/PQRI Conference on Advancing Product Quality

2nd FDA/PQRI Conference on Advancing Product Quality 2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President

More information

A Review on Process Validation of Pharmaceutical Manufacturing Processes

A Review on Process Validation of Pharmaceutical Manufacturing Processes B. Venkateswara Reddyet al ISSN:2347-4742 JPBMAL, 2014, Vol.2(1):105-111 Review Article Journal of Pharmaceutical and Biomedical Analysis Letters www.pharmaresearchlibrary.com/jpbmal A Review on Process

More information

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Ajit S. Narang, Ph.D. Bristol-Myers Squibb, Co. 2 nd FDA/PQRI Conference on Advancing Product Quality Bethesda,

More information

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space

Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies. Case No. RMWG-07. Space Manufacturing Technology Committee Risk Management Working Group Risk Management Case Studies Case Study Title: Defining Process Design Space Case No. RMWG-07 GMP System Impacted: Introduction / Background

More information

PLANKSTADT EXPERTS TAKING CARE

PLANKSTADT EXPERTS TAKING CARE CordenPharma PLANKSTADT EXPERTS TAKING CARE Our History 1977 - Start of Packaging activities (ICI Pharma) 1980 - Start of Formulation activities (ICI Pharma) 1995 - First Pre-approval Inspection by FDA

More information

PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission

PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets. Part 1: Concept and Principles Part 2: Mock P2 Submission PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets Part 1: Concept and Principles Part 2: Mock P2 Submission 1 Part 1 Concept and Principles Introduction Rationale Concept

More information

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma

Roller compactors for the pharmaceutical industry. BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma Roller compactors for the pharmaceutical industry BT 120 Pharma WP 120 Pharma WP 150 Pharma WP 200 Pharma Roller compactors for the pharmaceutical industry Compaction and granulation in the pharmaceutical

More information

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1

INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage

More information

Application of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013

Application of PAT for Tablet Analysis. Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Application of PAT for Tablet Analysis Case examples from Novartis Lorenz Liesum, Lead PAT Hamburg, 19 th of April 2013 Agenda PAT@Novartis Organization Business Drivers and Cases NIR Spectroscopy for

More information

Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon

Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression. Katie Hewlett, Dow Gus LaBella, Colorcon Streamlined Manufacture of Modified Release Matrix Tablets via Direct Compression Katie Hewlett, Dow Gus LaBella, Colorcon Controlled Release Alliance Unique Together Leading polymer expertise Quality

More information

A Compilation of WHO GMP Audit Points

A Compilation of WHO GMP Audit Points A Compilation of WHO GMP Audit Points Collected from WHOPIR of 28 companies Part III of VIII Current article Part III Production Prepared and Submitted By: Edited by : A. Jwalakanth B.Pharm, MBA (Aus)

More information

Malukani et al., IJPSR, 2012; Vol. 3(7): ISSN:

Malukani et al., IJPSR, 2012; Vol. 3(7): ISSN: IJPSR (2012), Vol. 3, Issue 07 (Research Article) Received on 27 March, 2012; received in revised form 17 June, 2012; accepted 25 June, 2012 PROCESS VALIDATION OF SOTALOL HYDROCHLORIDE TABLETS J.N. Malukani*

More information

Process Validation And Risk Assessment Study of Loratadine Tablet

Process Validation And Risk Assessment Study of Loratadine Tablet Vol: 3 Issue: 1 Process Validation And Risk Assessment Study of Loratadine Tablet *1 2 2 2 Vala Khushbu, Patel Chaitali, Rathava Rakesh, Rathod Dhara 1 Department of Pharmaceutical Chemistry, Parul Institute

More information

Quality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms

Quality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms CPhI Worldwide 2017 October 24 th -v 26 th, 2017 Frankfurt Quality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms Lucile KOWALSKI - NPI Project Manager Guy VERGNAULT

More information

Parajuli et al Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 1

Parajuli et al Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 1 Parajuli et al Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 1 Available online on 15.11.2015 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open access to Pharmaceutical

More information

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.

PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation

More information

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. FDA Perspective on the Use of Process Capability FDA Perspective on the Use of Process Capability Chunsheng Cai, Ph.D. Office of Process and Facilities Office of Pharmaceutical Quality, CDER, FDA 2017 ISPE Annual Meeting & Expo Disclaimer This presentation

More information

PREPARATION OF RAW MATERIALS AND SHAPING OF CERAMIC TILES

PREPARATION OF RAW MATERIALS AND SHAPING OF CERAMIC TILES PREPARATION OF RAW MATERIALS AND SHAPING OF CERAMIC TILES INTRODUCTION: RAW MATERIALS FOR THE PRODUCTION OF CERAMIC TILES Mariano Paganelli FIRST PART: RAW MATERIALS PREPARATION Chapter 1. BODY FORMULATION

More information

Industry Perspective on Lifecycle Management

Industry Perspective on Lifecycle Management Industry Perspective on Lifecycle Management and Post-Approval Building Changes the Best title here Focus on Quality by Design FDA/PQRI Conference on Evolving Product Quality Sep. 16-17, 2014 Michael Kimball

More information

Providing insight into pharmaceutical formulations

Providing insight into pharmaceutical formulations Providing insight into pharmaceutical formulations Dr Steve Ward-Smith Pharmaceutical Industry The average cost of developing a drug is reported to be approx $500 million, but up to 70% of new chemical

More information

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA

Managing Quality in Pharmaceutical Industry Using Six Sigma. Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Managing Quality in Pharmaceutical Industry Using Six Sigma Edited by Mahmoud Farouk Moussa TQM, CSSBB, MBA Outlines Pharmaceutical Manufacturing Process and Drug Product Quality. Process Excellence Approach

More information

Implementation of QBD for Analytical Methods - Session Introduction -

Implementation of QBD for Analytical Methods - Session Introduction - Implementation of QBD for Analytical Methods - Session Introduction - Sonja Sekulic January 24, 2014 Quality by Design (QbD) A Systematic Approach ICH Q8(R2) Product Profile Define quality target product

More information

PROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS

PROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS P a g e 68 Asian Journal of PHARMACEUTICAL RESEARCH Journal homepage: - www.ajprjournal.com e-issn 2231 363X Print ISSN 2231 3621 PROCESS VALIDATION OF ZOLPIDEM TARTRATE 5 mg FILM COATED TABLETS Parixit

More information

Engineering in Chemical and Pharmaceutical Processes. Compressing the powder between two surfaces

Engineering in Chemical and Pharmaceutical Processes. Compressing the powder between two surfaces Engineering in Chemical and Pharmaceutical Processes Particle sizing, Compaction, Extrusion Compaction Dry-granulation Principle Compressing the powder between two surfaces Cohesive forces van der Waals

More information

Measuring and understanding. of powders with the FT4 Powder Rheometer. freemantechnology

Measuring and understanding. of powders with the FT4 Powder Rheometer. freemantechnology Measuring and understanding of powders with the FT4 Powder Rheometer freemantechnology A universal powder tester The FT4 Powder Rheometer was originally designed to This remains a primary function today,

More information

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE? WHITEPAPER TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE? { To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block

More information

7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben

7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben 7th Training School on Microencapsulation Strasbourg Februar 2015 1 Dr. Anne Ettner, Glatt Pharmaceutical Services 2 Overview 1. Introduction 2. Fluid bed equipment 3. Basics of fluid bed Wurster technology

More information

Dal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale

Dal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale Compliance GMP e regolatoria: novità e aggiornamenti MILANO 2 maggio 2018 Dal Quality by Design alla Process Validation nel processo di sviluppo di un medicinale Dr. Maurizio Valleri A.Menarini Manufacturing

More information

PROCESS VALIDATION ANSM 2015 FDA 2011

PROCESS VALIDATION ANSM 2015 FDA 2011 PROCESS VALIDATION ANSM 2015 FDA 2011 PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Qualified Consultant At the measure 2 of the Levier Program PBE, Training Company Agreement CPMT #0059104

More information

Agenda. Applying Quality by Design to Generic Drug Manufacturing. Bikash Chatterjee President & CTO Pharmatech Associates

Agenda. Applying Quality by Design to Generic Drug Manufacturing. Bikash Chatterjee President & CTO Pharmatech Associates Applying Quality by Design to Generic Drug Manufacturing Bikash Chatterjee President & CTO Pharmatech Associates 1 Agenda What is QbD? Why it has become important What companies need to know, overview

More information

Approval Application Form for Sakura Bloom Tablets

Approval Application Form for Sakura Bloom Tablets Approval Application Form for Sakura Bloom Tablets Mock-up for Columns of Manufacturing Methods and Specifications & Test Methods for Drug Products (sample description) Study project for regulatory harmonization

More information

ADVANTAGES OF MULTIPARTICULATES (PELLETS):

ADVANTAGES OF MULTIPARTICULATES (PELLETS): INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage

More information

Association. Case Study 3. achieving real time release testing by a

Association. Case Study 3. achieving real time release testing by a Case Study 3 Applying PDA: QbD for A a legacy Global product and achieving real time release testing by a design Association space approach with supportive PAT and soft sensor based models: Challenges

More information

Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010

Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process

More information

Potent Manufacturing of Solid Oral Dosages Utilizing Dry Granulation

Potent Manufacturing of Solid Oral Dosages Utilizing Dry Granulation Potent Manufacturing of Solid Oral Dosages Utilizing Dry Granulation Shantanu Sonparote AbbVie Associate Process Development Engineer, AbbVie Manufacturing Science & Technology March 18, 2014 Potent Manufacturing

More information

Impact factor: 3.958/ICV: 4.10 ISSN:

Impact factor: 3.958/ICV: 4.10 ISSN: Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 312 Pharma Science Monitor 9(2),Apr-Jun 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com

More information

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES REVISED

More information

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System

Agilent TRS100 Raman. Quantitative Pharmaceutical Analysis System Agilent TRS100 Raman Quantitative Pharmaceutical Analysis System Agilent TRS100 Raman Streamlined Quality Control Fast Test hundreds of intact tablets or capsules in minutes Simple Quantify active pharmaceutical

More information

Continuous Manufacturing: An Industry View

Continuous Manufacturing: An Industry View Novartis Pharmaceuticals Continuous Manufacturing: An Industry View Diane Zezza Novartis Pharmaceuticals FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Where are we today? Continuous Manufacturing

More information

Review Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.

Review Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M. Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2015; 4(6): 324-330 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com

More information

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production

Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Seamless Integration of a Semi- Continuous Coating Process into Existing Solid Dosage Production Abstract A study was conducted using the KOCO 25 in conjunction with the ROB 50, in order to provide insight

More information

Particle Size Reduction MILLING TECHNOLOGY

Particle Size Reduction MILLING TECHNOLOGY Material Processing Technologies Pharmaceutical Technologies International, Inc. Princeton, New Jersey, USA Particle Size Reduction MILLING TECHNOLOGY Presented by: Mina Ibrahim, P.Eng., MBA Product Manager,

More information

Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA

Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Product, Process Knowledge & SPC: PV Lifecycle Approach IFPAC January 2016, Arlington, VA Naheed Sayeed Manager, Technical Operations Process Validation, Apotex Inc. 1 Process Validation Life Cycle Stage

More information

Future of Question-based Review and Regulatory Submissions

Future of Question-based Review and Regulatory Submissions Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product

More information

Formulation Development & CTM Manufacturing Services

Formulation Development & CTM Manufacturing Services Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range

More information

Multi Purpose Attachment

Multi Purpose Attachment oating > Mixing > Grinding > Stirring > Kneading > Granulating > Filling > Homogenising > > Stirring > Kneading > Granulating > Filling > Homogenising > Pelletizing > Sieving > Sha > Dosing > Coating >

More information

Analytical and formulation attributes

Analytical and formulation attributes Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding

More information

COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS

COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS Additional guidance for manufacturers This note identifies the most common quality related deficiencies in recently assessed dossiers

More information

Process Validation Guidelines. Report highlights 23 rd February 2018

Process Validation Guidelines. Report highlights 23 rd February 2018 Process Validation Guidelines Report highlights 23 rd February 2018 Process validation is an important element of pharmaceutical quality system An effective system provides assurance of the continued capability

More information

Successful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world

Successful Tableting Supplement. Continuous Tableting MODUL Q A-Type Tooling. engineering for a better world Successful Tableting Supplement Continuous Tableting MODUL Q A-Type Tooling engineering for a better world Why GEA? Operational excellence For more than a hundred years, our innovation, driven by our passion

More information

Table Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008)

Table Formula of Levodopa + Benserazide HCl capsule (batch no. 004 to 008) Introduction After using pearlitol SD (200) along with avicel ph 112 the flow of the blend was improved but still not up to the mark. Weight variation was observed around (11.47%) which was not acceptable.

More information

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms Introduction to the Example This is an example pharmaceutical development report illustrating how ANDA applicants can move toward

More information

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork

Implementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering

More information

On-Demand Manufacturing of Pharmaceuticals

On-Demand Manufacturing of Pharmaceuticals On-Demand Manufacturing of Pharmaceuticals Innovation in continuous filtration, drying and formulation of drugs International Symposium on Continuous Manufacturing of Pharmaceuticals Salvatore Mascia Sep

More information

Formulation Development Services. Your trust is our reward

Formulation Development Services. Your trust is our reward Formulation Development Services. Your trust is our reward Index Who we are? Mission and Vision Where we can help you? Infrastructure and Systems Site Plan Services we offer Technologies we practice Quality

More information

California Grain & Feed Industry Conference Monterey Bay January 16, 2019

California Grain & Feed Industry Conference Monterey Bay January 16, 2019 California Grain & Feed Industry Conference Monterey Bay January 16, 2019 1 Page 1 Evonik Power to cr Improving Production Efficiency Presented by: Mark Daniel 2 Improving Production Efficiency Combination

More information

Pharmaceutical Manufacturing Technology Centre

Pharmaceutical Manufacturing Technology Centre Pharmaceutical Manufacturing Technology Centre Research themes for Initial Research Programme Call for Proposals The Centre will focus on advanced pharmaceutical manufacturing technologies with an initial

More information